Nexstim: The end of the year laid a firmer foundation for the future
The key figures were already known based on preliminary data from the beginning of the year, which were now revised. Revenue was slightly higher than the preliminary data suggested and the result hit our forecasts. The H2 cash flow was also at the expected zero level considering the partial transfer of cash flow to 2024 through increased trade receivables. The report did not contain any surprises, so forecast changes were small. Nexstim expects increasing revenue and earnings, which disperses concerns related to cash flow adequacy. We expect the company to continue on the path of profitable growth, although the cashflow is likely to remain negative this year.
Nexstim
Nexstim är verksamt inom medicinteknik. Bolaget har utvecklat en icke-invasiv teknik för hjärnstimulering som kallas SmartFocus®. Det är en navigerad magnetisk stimuleringsteknik (nTMS) med 3D-navigering som ger inriktning av TMS till det specifika området av hjärnan. Tekniken är avsedd för behandling av svår depression och kronisk neuropatisk smärta. Bolaget grundades år 2000 och har sitt huvudkontor i Helsingfors.
Read more on company pageKey Estimate Figures03/01
2022 | 23e | 24e | |
---|---|---|---|
Omsättning | 9,5 | 7,0 | 8,8 |
tillväxt-% | 48,91 % | −26,56 % | 25,72 % |
EBIT (adj.) | 0,8 | −1,1 | −0,4 |
EBIT-% | 8,79 % | −15,65 % | −4,79 % |
EPS (adj.) | 0,18 | −0,17 | −0,07 |
Utdelning | 0,00 | 0,00 | 0,00 |
Direktavkastning | |||
P/E (just.) | 22,85 | - | - |
EV/EBITDA | 22,00 | - | 116,98 |
![](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90/https://forum.inderes.se/letter_avatar_proxy/v4/letter/b/b487fb/500.png)
![](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90/https://forum.inderes.se/user_avatar/forum.inderes.se/pia_maljanen/500/735_2.png)
![](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90/https://forum.inderes.se/letter_avatar_proxy/v4/letter/b/b487fb/500.png)